XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.1
License Agreements - Syndax (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended
Dec. 09, 2021
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2022
Mar. 31, 2021
Long term investments   $ 221,266 [1]   $ 174,681  
Research and Development Expense       353,373 $ 306,896
Unrealized gain (loss) on long term investments       (46,585) $ (27,709)
Investment in Syndax          
Long term investments   31,100   $ 24,700  
Ownership percentage (as a percent)       3.00%  
Unrealized gain (loss) on long term investments       $ (6,400)  
Syndax | Development and Regulatory Milestones | Maximum          
Additional milestone payments under the license agreement     $ 220,000    
Syndax | Commercialization Milestones | Maximum          
Additional milestone payments under the license agreement     $ 230,000    
Syndax          
Upfront payment under license agreement   $ 117,000      
Syndax | Syndax | U.S.          
Funding of future development costs (as a percent)     45.00%    
Syndax | Incyte | U.S.          
Funding of future development costs (as a percent)     55.00%    
Stock purchase agreement | Investment in Syndax          
Purchase of common stock under Stock Purchase Agreement (in shares )     1.4    
Equity Method Investment, Aggregate Cost $ 35,000   $ 35,000    
Per share price $ 17.48   $ 24.62    
Lock-up period     6 months    
Long term investments $ 24,800        
Research and Development Expense $ 10,200        
[1] The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date.